The Centers for Medicare & Medicaid Services (CMS) placed its final rule into force on October 13, 2026, declaring that federal Medicaid and Children’s Health Insurance Program (CHIP) dollars may no longer be used for any sex-rejecting procedures performed on patients younger than 18 (Medicaid) or 19 (CHIP). The agency prefers the term SRP over “gender-affirming care,” arguing that the latter understates the potentially irreversible nature of the interventions. The rule defines SRPs as any pharmaceutical or surgical measure intended to align an individual’s body with an identity that differs from the sex assigned at birth.
More than 11,000 comments were lodged during the public-comment period, and over ninety percent opposed the proposal. CMS concluded that the scientific evidence supporting the benefits of these interventions for children is of “very low quality,” and it cited reviews indicating that broad use of such treatments in the pediatric population is not justified.
Projected fiscal impact and spending trends
In 2023, Medicaid and CHIP paid roughly $23.8 million for hormone therapy directed at youths aged 6-17, with puberty blockers accounting for about 88 percent of that sum. Adding inpatient, outpatient, and prescription-drug claims linked to diagnoses of transsexualism or gender-identity disorders brings total computable Medicaid/CHIP expenditures for these services to around $31 million for that year.
The regulatory-impact analysis attached to the final rule forecasts a cumulative reduction of $235 million in federal and state Medicaid/CHIP outlays over fiscal years 2027-2036. Of that, the federal government is projected to save roughly $138 million, while states would collectively cut about $97 million. States that had not previously barred gender-related treatments for minors contributed roughly three-quarters of the current spend, making them the primary beneficiaries of the projected cuts.
Clinical ramifications for children and adolescents
Under the new regulation, puberty blockers and any gender-related surgeries lose federal coverage immediately on the rule’s effective date. For patients already receiving cross-sex hormone therapy, CMS provides a six-month “tapering-off” window during which Medicaid and CHIP will continue to reimburse those medications before the funding ceases.
The rule expressly preserves coverage for mental-health services. Medicaid’s Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) provisions, as well as CHIP’s mandate for necessary mental-health care, remain unchanged. CMS highlighted a Department of Health and Human Services review that found psychotherapy to be a safer, non-invasive first-line option, a stance echoed by medical authorities in Sweden, Finland, and the United Kingdom.
Legal battles and political fallout
Two separate lawsuits have already challenged the rule. In September, a coalition of 21 states and the District of Columbia sued the Department of Health and Human Services, alleging that the rule is “arbitrary and capricious” and exceeds the agency’s statutory authority under the Administrative Procedure Act. A second suit filed by families of transgender children in New Hampshire raises the same procedural objections.
The CMS action arrives amid a broader Trump-administration push to curtail gender-affirming care for minors. Federal investigators have examined more than twenty pediatric hospitals, seeking records to assess potential fraud. Several institutions—including the University of Pittsburgh Medical Center and others—have settled with the Justice Department, agreeing to discontinue gender-related treatments for children and to pay sizable penalties. Children’s Hospital of Philadelphia successfully blocked a subpoena for patient records, while Nemours Health System declined comment.
Twenty-one Democratic-led states and D.C. have filed a federal suit seeking to overturn the rule, arguing that it infringes on states’ authority to determine Medicaid benefits and creates unlawful barriers for low-income families. Pennsylvania, Delaware, and New Jersey, all part of the lawsuit, have announced plans to finance the prohibited services with state money. Pennsylvania will cover puberty blockers and hormone therapy for Medicaid enrollees, though it cannot fund comparable CHIP services. Delaware’s Governor Matt Meyer pledged to replace the lost federal dollars in full, emphasizing that medical necessity—not political considerations—should drive care decisions.
